Illumina Inc (ILMN) Stock Price, Quote & News

Company Profile

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other g...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 858 202 4500

Fax: 858 202 4766

Website: www.illumina.com

Address:

5200 Illumina Way, San Diego, United States

ChessGM Mar. 19 at 4:27 PM

$ILMN https://youtu.be/aL5D4XqRo-8!

0 · Reply

james899 Mar. 19 at 1:34 PM

$ILMN price action seems to indicate stable buying, no? I see a lot of red but this one doesn't go down much

0 · Reply

Nosh Mar. 12 at 8:09 PM

$ILMN I guess this one will come close to tagging $100.

0 · Reply

ZacksResearch Mar. 11 at 1:09 PM

$ILMN surges 44.8% over the past year — what's fueling this renowned genomics company? 🚀 🌱 Strong growth in core sequencing and multiomics 📊 Margin expansion + solid cash position ⚠️ China ban on NGS sequencers is a big challenge Find out what could drive Illumina’s next move 👉 https://www.zacks.com/stock/news/2882084/illumina-stock-climbs-448-in-a-year-whats-driving-the-rally?cid=sm-stocktwits-2-2882084-body-36917&ADID=SYND_STOCKTWITS_TWEET_2_2882084_BODY_36917

0 · Reply

ZacksResearch Mar. 11 at 12:09 PM

$ILMN up 44.8% in a year — and the growth engine might just be getting started 🚀 Strong demand for NovaSeq X sequencing, broader NGS testing adoption, expanding multiomics capabilities, and improving margins have been key drivers behind the stock’s surge over the past year. Find out what’s fueling the momentum 👉 https://www.zacks.com/stock/news/2882084/illumina-stock-climbs-448-in-a-year-whats-driving-the-rally?cid=sm-stocktwits-2-2882084-teaser-36903&ADID=SYND_STOCKTWITS_TWEET_2_2882084_TEASER_36903

0 · Reply

cubie Mar. 9 at 5:59 PM

$AMFN $ELPW $ILMN Sorry cubie enjoys making fun of 3 cent penny sht pumpers. U doubled ur money from 1 cent to 2 cents. But still down -80%!!!!! Lmao🤔😂🤣

1 · Reply

Estimize Mar. 4 at 4:07 PM

Wall St is expecting 1.06 EPS for $ILMN Q1 [Reporting 04/28 AMC] http://www.estimize.com/intro/ilmn?chart=historical&metric_name=eps&utm_co

0 · Reply

Streetdilly1 Mar. 3 at 12:59 AM

$FLGT why wouldnt illumina $ILMN or revity $RVTY bid $20 and take the other $6 a share in cash for free +get revenues, platform etc for free.

3 · Reply

Nosh Feb. 27 at 9:56 PM

$ILMN added.

0 · Reply

notreload_ai Feb. 27 at 3:17 PM

TD Cowen notes Roche's $150 per genome consumables price for its new Axelios nanopore sequencer came in higher than expected, offering short-term relief to $ILMN market position. https://notreload.xyz/roche-axelios-pricing-gives-illumina-breathing-room/

0 · Reply

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

ILMN LH

Mar 16, 2026, 9:15 AM EDT - 5 days ago

Illumina advances preventive genomics through strategic consortium with Veritas Genetics

ILMN

Mar 5, 2026, 9:15 AM EST - 16 days ago

Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

ILMN

Feb 27, 2026, 9:15 AM EST - 22 days ago

Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida

ILMN

Feb 26, 2026, 8:00 AM EST - 23 days ago

Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026

ILMN

Feb 25, 2026, 9:15 AM EST - 24 days ago

Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics

ILMN

Feb 24, 2026, 12:15 PM EST - 25 days ago

Illumina launches TruPath Genome, setting a new standard in genomic insight

ILMN

Feb 23, 2026, 9:15 AM EST - 26 days ago

Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

ILMN

Feb 17, 2026, 3:10 PM EST - 4 weeks ago

Illumina To Webcast Upcoming Investor Conference

ILMN

Feb 5, 2026, 4:06 PM EST - 6 weeks ago

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

ILMN

Feb 3, 2026, 9:15 AM EST - 6 weeks ago

Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally

ILMN

Jan 30, 2026, 9:05 AM EST - 7 weeks ago

Illumina completes acquisition of SomaLogic

ILMN

Jan 20, 2026, 1:19 PM EST - 2 months ago

Illumina Gets Medicare Boost for Cancer Test, Shares Climb

ILMN

Jan 20, 2026, 9:15 AM EST - 2 months ago

Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology

ILMN

Jan 13, 2026, 9:18 AM EST - 2 months ago

Illumina unveils dataset to speed up AI-powered drug discovery

ILMN

Jan 13, 2026, 9:15 AM EST - 2 months ago

Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery

ILMN

Jan 13, 2026, 9:00 AM EST - 2 months ago

Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

ILMN

Jan 12, 2026, 4:07 PM EST - 2 months ago

Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026

ILMN

Jan 8, 2026, 4:30 PM EST - 2 months ago

Illumina Appoints Dr. Eric Green as Chief Medical Officer

ILMN

Jan 8, 2026, 8:07 AM EST - 2 months ago

Illumina and PREMIA partner to expand clinical access to CGP in Asia

ILMN

Jan 6, 2026, 9:15 AM EST - 2 months ago

Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis

ILMN

Dec 16, 2025, 2:29 PM EST - 3 months ago

Santa Rally Looms: These 5 Stocks Often Deliver Gifts To Investors

CAT FCX GS ILMN JPM

Dec 11, 2025, 9:15 AM EST - 3 months ago

Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually

ILMN

Nov 12, 2025, 12:00 PM EST - 4 months ago

Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study

ILMN

Nov 10, 2025, 1:16 PM EST - 4 months ago

Final Trades: Morgan Stanley, Cisco Systems, Illumina and FTAI Aviation

CSCO FTAI ILMN MS

Nov 10, 2025, 12:15 PM EST - 4 months ago

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

ILMN LAB

Nov 5, 2025, 5:16 PM EST - 4 months ago

Illumina Responds to Positive Updates from Chinese Ministry of Commerce

ILMN

Oct 31, 2025, 12:01 PM EDT - 5 months ago

DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars

ILMN

Oct 30, 2025, 4:05 PM EDT - 5 months ago

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025

ILMN

Oct 20, 2025, 4:21 PM EDT - 5 months ago

Final Trades: Illumina, Columbia Banking, Alibaba and JPMorgan Chase

BABA COLB ILMN JPM

Oct 15, 2025, 9:15 AM EDT - 5 months ago

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights

ILMN

Oct 15, 2025, 9:15 AM EDT - 5 months ago

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot

ILMN WGS

Oct 14, 2025, 4:05 PM EDT - 5 months ago

Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025

ILMN

Oct 1, 2025, 9:05 AM EDT - 6 months ago

Illumina launches new business to accelerate technology and data-driven discovery

ILMN

Sep 26, 2025, 9:40 AM EDT - 6 months ago

ILMN Stock vs. IQV Stock

ILMN IQV

Sep 23, 2025, 9:15 AM EDT - 6 months ago

Illumina advances personalized cancer care with new pharma development partnerships

ILMN

Sep 18, 2025, 9:15 AM EDT - 6 months ago

Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

ALNY ILMN

Sep 3, 2025, 9:15 AM EDT - 7 months ago

Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

ILMN LAB

Aug 1, 2025, 12:02 PM EDT - 8 months ago

These Analysts Boost Their Forecasts On Illumina Following Upbeat Results

ILMN

Jul 31, 2025, 4:05 PM EDT - 8 months ago

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

ILMN

Jul 30, 2025, 9:15 AM EDT - 8 months ago

Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling

ILMN

Jul 17, 2025, 7:45 AM EDT - 8 months ago

Illumina Stock: What Went Wrong And Why It's Best To Stay Away

ILMN

Jul 10, 2025, 4:05 PM EDT - 9 months ago

Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

ILMN

Jul 10, 2025, 9:15 AM EDT - 9 months ago

Illumina named to TIME's World's Most Sustainable Companies list for the second consecutive year

ILMN

Jun 23, 2025, 7:13 AM EDT - 9 months ago

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

ILMN LAB

Jun 18, 2025, 9:00 AM EDT - 9 months ago

Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

ILMN

Jun 10, 2025, 4:01 PM EDT - 10 months ago

lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics

ILMN

May 29, 2025, 2:01 PM EDT - 10 months ago

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

ILMN

May 28, 2025, 12:22 PM EDT - 10 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD IBB ILMN NVS

May 28, 2025, 9:15 AM EDT - 10 months ago

Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies

ILMN

ChessGM Mar. 19 at 4:27 PM

$ILMN https://youtu.be/aL5D4XqRo-8!

0 · Reply

james899 Mar. 19 at 1:34 PM

$ILMN price action seems to indicate stable buying, no? I see a lot of red but this one doesn't go down much

0 · Reply

Nosh Mar. 12 at 8:09 PM

$ILMN I guess this one will come close to tagging $100.

0 · Reply

ZacksResearch Mar. 11 at 1:09 PM

0 · Reply

ZacksResearch Mar. 11 at 12:09 PM

0 · Reply

cubie Mar. 9 at 5:59 PM

$AMFN $ELPW $ILMN Sorry cubie enjoys making fun of 3 cent penny sht pumpers. U doubled ur money from 1 cent to 2 cents. But still down -80%!!!!! Lmao🤔😂🤣

1 · Reply

Estimize Mar. 4 at 4:07 PM

Wall St is expecting 1.06 EPS for $ILMN Q1 [Reporting 04/28 AMC] http://www.estimize.com/intro/ilmn?chart=historical&metric_name=eps&utm_co

0 · Reply

Streetdilly1 Mar. 3 at 12:59 AM

$FLGT why wouldnt illumina $ILMN or revity $RVTY bid $20 and take the other $6 a share in cash for free +get revenues, platform etc for free.

3 · Reply

Nosh Feb. 27 at 9:56 PM

$ILMN added.

0 · Reply

notreload_ai Feb. 27 at 3:17 PM

0 · Reply

Estimize Feb. 25 at 5:03 PM

Wall St is expecting 1.06 EPS for $ILMN Q1 [Reporting 04/28 AMC] http://www.estimize.com/intro/ilmn?chart=historical&metric_name=eps&utm_co

0 · Reply

OfficialStocktwitsUser Feb. 24 at 9:31 PM

$ILMN RSI: 33.95, MACD: -5.6940 Vol: 13.10, MA20: 128.12, MA50: 135.55 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MissionImpossibl Feb. 20 at 3:55 PM

$GRAL $ILMN should go up now !! Good buys at $50 s

0 · Reply

MissionImpossibl Feb. 19 at 11:16 PM

$GRAL $ILMN will do fine ! Just hold long term , will hit back $100 again .

0 · Reply

MissionImpossibl Feb. 19 at 10:44 PM

$GRAL $ILMN Illumina bought GRAIL for ~$8B.REGULATORS blocked it → forced spin. GRAIL IPO’d at ~$25. Today ~ crashed to $55 Market cap 1.5b — still far below the original buy price.

1 · Reply

100Financial Feb. 19 at 12:15 AM

$UBER $ILMN $AMZN $QQQ $SPY All three tickers from yesterday's pick went up 2-3% today. Our top three picks for tomorrow are: UBSR ILMN AMZN All three are identified in a short term bullish pattern. As clarified numerous times, our picks are not for a long term hold. The average hold time is 1-3 days for quick scalping and compounding. GL and happy trading. As always, full trade setups, price targets, trading strategies etc are available to premium members only.

0 · Reply

BillionerOfKing Feb. 18 at 4:40 AM

$ILMN Current Stock Price: $116.50 Contracts to trade: $115.0 ILMN Feb 20 2026 Call Entry: $2.40 Exit: $3.10 ROI: 29% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SuperGreenToday Feb. 17 at 9:56 PM

$ILMN Share Price: $116.50 Contract Selected: Sep 18, 2026 $115 Calls Buy Zone: $13.34 – $16.48 Target Zone: $23.03 – $28.15 Potential Upside: 63% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ZacksResearch Feb. 12 at 4:20 PM

$ILMN beats Q4 estimates but shares tumble 10.4% — what's spooking investors? 🤔 Despite a 7.4% EPS beat and 5.4% year-over-year revenue growth in Q4, concerns over gross margin contraction are weighing on the stock. 📉 Full breakdown here 👉 https://www.zacks.com/stock/news/2861538/illumina-q4-earnings-revenues-top-estimates-stock-dips?cid=sm-stocktwits-2-2861538-body-33313&ADID=SYND_STOCKTWITS_TWEET_2_2861538_BODY_33313

0 · Reply

ZacksResearch Feb. 12 at 3:20 PM

$ILMN crushed Q4… so why did the stock drop 10%? 🤔 The company topped Q4 EPS and revenue estimates and delivered a 42% profit jump, but margin concerns overshadowed the strong print — even with a 2026 growth outlook on the table. ⚠️ Is this a short-term overreaction or a real red flag? Full breakdown here 👉 https://www.zacks.com/stock/news/2861538/illumina-q4-earnings-revenues-top-estimates-stock-dips?cid=sm-stocktwits-2-2861538-teaser-33312&ADID=SYND_STOCKTWITS_TWEET_2_2861538_TEASER_33312

0 · Reply

kb60521 Feb. 9 at 9:52 PM

$ILMN Any longtimer here? what are your thoughts and expectations? can you please share...

1 · Reply

Market Cap	18.80B
Revenue (ttm)	4.34B
Net Income (ttm)	850.00M
EPS (ttm)	N/A
PE Ratio	25.35
Forward PE	23.94
Profit Margin	19.57%
Debt to Equity Ratio	0.55

Volume	2,663,900
Avg Vol	2,165,264
Day's Range	N/A - N/A
Shares Out	152.90M
Stochastic %K	70%
Beta	1.45
Analysts	Sell
Price Target	$133.95